Coastal Infusion Administers Vimizim®

Vimizim (elosulfase alfa) is used to treat patients with mucopolysaccharidosis type IVA (MPS IVA, also known as Morquio A syndrome). This disease is caused by the lack of an enzyme called N-acetylgalactosamine-6-sulfatase. If the enzyme is not present, or only present in small quantities, GAGs cannot be broken down and they build up in bones and organs. This causes the signs of the disease, the most noticeable being short bones, difficulty moving and breathing, clouding of the eyes and hearing loss.

The active substance in Vimizim, elosulfase alfa, is a copy of the human enzyme N-acetylgalactosamine-6-sulfatase. The replacement enzyme helps to break down GAGs and stop them building up in cells, thereby improving the symptoms of MPS IVA.

What It Treats

Vimizim is used to treat Mucopolysaccharidosis type IVA (MPS IVA) (Morquio A Syndrome).

Prescribed By

Vimizim is most often prescribed by Geneticists.

How it’s Administered

Vimizim is administered by intravenous infusion. Vimizim infusions take 3 – 5 hours.

Frequency

Vimizim is generally administered every four weeks after three loading doses at 14-day intervals.

Additional Resources

• Vimizim Website
• Prescribing Information
• Co-Pay Assistance

The information on this page is compiled from a variety of online sources. Coastal Infusion has made every effort to verify its accuracy, but patients are advised to discuss any planned or current treatments with their doctor. Report inaccuracies